Global Survey on the Impact of Decentralized Clinical Trials (DCTs) on Sponsor-CRO Collaborations
The Tufts Center for the Study of Drug Development at the Tufts University School of Medicine is conducting an ambitious global study to characterize and benchmark the impact of decentralized clinical trials (DCTs) on sponsor-CRO collaborations. This is one of the most comprehensive surveys of its kind among clinical research professionals and it will gather critical baselines to compare against future results. We are focused on gaining insights and perceptions on this topic across a wide range of organizations and appreciate your time on this research.
Please click on the link below to complete the survey: Take the Survey
The survey should take approximately 30 minutes of your time. Your responses will be strictly confidential and will only be reported in the aggregate; none of the study findings can be traced back to any individual or organization. A summary report of de-identified, aggregate results will be shared with 10 pharmaceutical companies and contract research organizations (CROs) that funded the study. In appreciation for completing the survey, we’ll send you a summary of the results. Thank you in advance for your participation in this important research effort!
Please complete the survey by March 25, 2022.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
